Longer survival was seen in those with melanoma who received programmed cell death receptor-1 or its ligand who had a low neutrophil-lymphocyte ratio.

The data shared today demonstrated that oral, once-daily mavorixafor was well tolerated and meaningfully elevated study participants’ blood neutrophil counts. With these new data and strong momentum ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

In November 2024 we received FDA Breakthrough Device Designation for the SCD for use in chronic dialysis, our first such designation for a chronic indication. This is our fourth FDA award of ...